Introduction Glucagon-like peptide-1 (GLP-1) increases insulin secretion from pancreatic beta-cells and GLP-1 receptor (GLP-1R) agonists are widely used as treatment for type 2 diabetes mellitus. Studying occupancy of the GLP-1R in various tissues is challenging due to lack of quantitative, repeatable assessments of GLP-1R density. The present study aimed to describe the quantitative distribution of GLP-1Rs and occupancy by endogenous GLP-1 during oral glucose tolerance test (OGTT) in pigs, a species that is used in biomedical research to model humans. Research design and methods GLP-1R distribution and occupancy were measured in pancreas and gastrointestinal tract by ex vivo autoradiography using the GLP-1R-specific radioligand 177Lu-exend...
AIMS: Radiolabeled Exendin-4 has been proposed as suitable imaging marker for pancreatic beta cell m...
Glucagon-like peptide 1 receptor (GLP-1R) imaging with radiolabeled exendin has proven to be a power...
Contains fulltext : 49645.pdf (publisher's version ) (Closed access)EXPERIMENTAL O...
Introduction Glucagon-like peptide-1 (GLP-1) increases insulin secretion from pancreatic beta-cells ...
Introduction Glucagon-like peptide-1 (GLP-1) increases insulin secretion from pancreatic beta-cells ...
Introduction Glucagon-like peptide-1 (GLP-1) increases insulin secretion from pancreatic beta-cells ...
Introduction Glucagon-like peptide-1 (GLP-1) increases insulin secretion from pancreatic beta-cells ...
Introduction Glucagon-like peptide-1 (GLP-1) increases insulin secretion from pancreatic beta-cells ...
Introduction Glucagon-like peptide-1 (GLP-1) increases insulin secretion from pancreatic beta-cells ...
Introduction Glucagon-like peptide-1 (GLP-1) increases insulin secretion from pancreatic beta-cells ...
Introduction The insulinotropic capacity of exogenous glucagon like peptide-1 (GLP-1) is reduced in ...
Diabetes epidemic is underway. Beta cell dysfunction (BCF) and loss of beta cell mass (BCM) are know...
Diabetes epidemic is underway. Beta cell dysfunction (BCF) and loss of beta cell mass (BCM) are know...
AIMS: Radiolabeled Exendin-4 has been proposed as suitable imaging marker for pancreatic beta cell m...
AIMS: Radiolabeled Exendin-4 has been proposed as suitable imaging marker for pancreatic beta cell m...
AIMS: Radiolabeled Exendin-4 has been proposed as suitable imaging marker for pancreatic beta cell m...
Glucagon-like peptide 1 receptor (GLP-1R) imaging with radiolabeled exendin has proven to be a power...
Contains fulltext : 49645.pdf (publisher's version ) (Closed access)EXPERIMENTAL O...
Introduction Glucagon-like peptide-1 (GLP-1) increases insulin secretion from pancreatic beta-cells ...
Introduction Glucagon-like peptide-1 (GLP-1) increases insulin secretion from pancreatic beta-cells ...
Introduction Glucagon-like peptide-1 (GLP-1) increases insulin secretion from pancreatic beta-cells ...
Introduction Glucagon-like peptide-1 (GLP-1) increases insulin secretion from pancreatic beta-cells ...
Introduction Glucagon-like peptide-1 (GLP-1) increases insulin secretion from pancreatic beta-cells ...
Introduction Glucagon-like peptide-1 (GLP-1) increases insulin secretion from pancreatic beta-cells ...
Introduction Glucagon-like peptide-1 (GLP-1) increases insulin secretion from pancreatic beta-cells ...
Introduction The insulinotropic capacity of exogenous glucagon like peptide-1 (GLP-1) is reduced in ...
Diabetes epidemic is underway. Beta cell dysfunction (BCF) and loss of beta cell mass (BCM) are know...
Diabetes epidemic is underway. Beta cell dysfunction (BCF) and loss of beta cell mass (BCM) are know...
AIMS: Radiolabeled Exendin-4 has been proposed as suitable imaging marker for pancreatic beta cell m...
AIMS: Radiolabeled Exendin-4 has been proposed as suitable imaging marker for pancreatic beta cell m...
AIMS: Radiolabeled Exendin-4 has been proposed as suitable imaging marker for pancreatic beta cell m...
Glucagon-like peptide 1 receptor (GLP-1R) imaging with radiolabeled exendin has proven to be a power...
Contains fulltext : 49645.pdf (publisher's version ) (Closed access)EXPERIMENTAL O...